Abeona Therapeutics (ABEO) Reports FDA RMAT Designation for EB-101 Gene Therapy in Epidermolysis Bullosa – StreetInsider.com
|
Abeona Therapeutics (ABEO) Reports FDA RMAT Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
StreetInsider.com Similar to Breakthrough Therapy designation, the RMAT allows companies developing regenerative medicine therapies to work more closely and frequently with the FDA, and RMAT-designated products may be eligible for priority review and accelerated … |
